ABSTRACT
Background and objective The treatment of psoriasis should not only focus on skin affectations but also weigh the parameters for health-related quality of life (HRQoL), thereby tackling the concept of cumulative life course impairment (CLCI) and treating the patient from a holistic perspective. The CRYSTAL study aimed to characterize psoriasis with real-word data from Spanish clinical practice in patients with moderate to severe disease who received continuous systemic treatment for at least 24 weeks by using the absolute Psoriasis Area and Severity Index (PASI) score and its correlation to HRQoL. Material and methods This was a non-interventional, cross-sectional study conducted in 30 centers in Spain, with 301 patients between the ages of 18 and 75 years. The study collected data regarding current treatment and absolute PASI and their relationship to HRQoL using the Dermatology Life Quality Index (DLQI), to activity impairment using the Work Productivity and Activity Impairment (WPAI) questionnaire, and to treatment satisfaction. Results The mean (SD) age was 50.5 (12.5) years, with a duration of disease of 14 (14.1) years. The mean (SD) absolute PASI reported was 2.3 (3.5), with 28.7% of patients presenting with PASI from >1 to ≤3 and 22.6% with PASI>3. Higher PASI scores were associated with higher DLQI (p<0.001) and WPAI scores and lower levels of treatment satisfaction (p<0.001). Conclusions These data indicate that achieving lower absolute PASI values may correlate not only with better HRQoL but also with better work productivity and treatment satisfaction (AU)
Antecedentes y objetivo El tratamiento de la psoriasis debe centrarse más allá de las afectaciones cutáneas, y valorar la calidad de vida relacionada con la salud (CVRS), abordando así el concepto de discapacidad acumulada en el transcurso vital y tratando al paciente desde una perspectiva holística. El estudio CRYSTAL tuvo como objetivo caracterizar la psoriasis con datos de la práctica clínica española en pacientes con enfermedad moderada a grave que recibieron tratamiento sistémico continuado durante al menos 24 semanas mediante la puntuación absoluta del Índice de la Severidad del área de Psoriasis (PASI) (medida del estado de la enfermedad en un momento dado y no por comparación con una puntuación basal) y su correlación con la CVRS. Material y métodos Se trata de un estudio no intervencionista, transversal, realizado en 30 centros de España, con 301 pacientes de edades comprendidas entre los 18 y los 75 años. Se recogieron datos relativos al tratamiento actual y al PASI absoluto y su relación con la CVRS mediante el Índice de Calidad de Vida en Dermatología (DLQI), con el deterioro de la actividad mediante el Cuestionario para el Deterioro de la Actividad y la Productividad Laboral (WPAI) y con la satisfacción con el tratamiento. Resultados La edad media (DE) fue de 50,5 (12,5) años, con una duración de la enfermedad de 14 (14,1) años. La media (DE) del PASI absoluto notificado fue de 2,3 (3,5), con 28,7% de pacientes que presentaban un PASI de > 1 a ≤ 3 y 22,6% con un PASI > 3. Las puntuaciones más altas del PASI se asociaron a puntuaciones más altas del DLQI (p < 0,001) y del WPAI y a niveles más bajos de satisfacción con el tratamiento (p < 0,001). Conclusiones Estos datos indican que alcanzar valores absolutos más bajos de PASI puede correlacionarse no solo con una mejor CVRS, sino también con una mejor productividad laboral y satisfacción con el tratamiento (AU)
Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Quality of Life , Psoriasis/epidemiology , Psoriasis/therapy , Severity of Illness Index , Cross-Sectional Studies , Surveys and Questionnaires , Spain/epidemiologyABSTRACT
Antecedentes y objetivo El tratamiento de la psoriasis debe centrarse más allá de las afectaciones cutáneas, y valorar la calidad de vida relacionada con la salud (CVRS), abordando así el concepto de discapacidad acumulada en el transcurso vital y tratando al paciente desde una perspectiva holística. El estudio CRYSTAL tuvo como objetivo caracterizar la psoriasis con datos de la práctica clínica española en pacientes con enfermedad moderada a grave que recibieron tratamiento sistémico continuado durante al menos 24 semanas mediante la puntuación absoluta del Índice de la Severidad del área de Psoriasis (PASI) (medida del estado de la enfermedad en un momento dado y no por comparación con una puntuación basal) y su correlación con la CVRS. Material y métodos Se trata de un estudio no intervencionista, transversal, realizado en 30 centros de España, con 301 pacientes de edades comprendidas entre los 18 y los 75 años. Se recogieron datos relativos al tratamiento actual y al PASI absoluto y su relación con la CVRS mediante el Índice de Calidad de Vida en Dermatología (DLQI), con el deterioro de la actividad mediante el Cuestionario para el Deterioro de la Actividad y la Productividad Laboral (WPAI) y con la satisfacción con el tratamiento. Resultados La edad media (DE) fue de 50,5 (12,5) años, con una duración de la enfermedad de 14 (14,1) años. La media (DE) del PASI absoluto notificado fue de 2,3 (3,5), con 28,7% de pacientes que presentaban un PASI de > 1 a ≤ 3 y 22,6% con un PASI > 3. Las puntuaciones más altas del PASI se asociaron a puntuaciones más altas del DLQI (p < 0,001) y del WPAI y a niveles más bajos de satisfacción con el tratamiento (p < 0,001). Conclusiones Estos datos indican que alcanzar valores absolutos más bajos de PASI puede correlacionarse no solo con una mejor CVRS, sino también con una mejor productividad laboral y satisfacción con el tratamiento (AU)
Background and objective The treatment of psoriasis should not only focus on skin affectations but also weigh the parameters for health-related quality of life (HRQoL), thereby tackling the concept of cumulative life course impairment (CLCI) and treating the patient from a holistic perspective. The CRYSTAL study aimed to characterize psoriasis with real-word data from Spanish clinical practice in patients with moderate to severe disease who received continuous systemic treatment for at least 24 weeks by using the absolute Psoriasis Area and Severity Index (PASI) score and its correlation to HRQoL. Material and methods This was a non-interventional, cross-sectional study conducted in 30 centers in Spain, with 301 patients between the ages of 18 and 75 years. The study collected data regarding current treatment and absolute PASI and their relationship to HRQoL using the Dermatology Life Quality Index (DLQI), to activity impairment using the Work Productivity and Activity Impairment (WPAI) questionnaire, and to treatment satisfaction. Results The mean (SD) age was 50.5 (12.5) years, with a duration of disease of 14 (14.1) years. The mean (SD) absolute PASI reported was 2.3 (3.5), with 28.7% of patients presenting with PASI from >1 to ≤3 and 22.6% with PASI>3. Higher PASI scores were associated with higher DLQI (p<0.001) and WPAI scores and lower levels of treatment satisfaction (p<0.001). Conclusions These data indicate that achieving lower absolute PASI values may correlate not only with better HRQoL but also with better work productivity and treatment satisfaction (AU)
Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Quality of Life , Psoriasis/epidemiology , Psoriasis/therapy , Severity of Illness Index , Cross-Sectional Studies , Surveys and Questionnaires , Spain/epidemiologyABSTRACT
BACKGROUND AND OBJECTIVE: The treatment of psoriasis should not only focus on skin affectations but also weigh the parameters for health-related quality of life (HRQoL), thereby tackling the concept of cumulative life course impairment (CLCI) and treating the patient from a holistic perspective. The CRYSTAL study aimed to characterize psoriasis with real-word data from Spanish clinical practice in patients with moderate to severe disease who received continuous systemic treatment for at least 24 weeks by using the absolute Psoriasis Area and Severity Index (PASI) score and its correlation to HRQoL. MATERIAL AND METHODS: This was a non-interventional, cross-sectional study conducted in 30 centers in Spain, with 301 patients between the ages of 18 and 75 years. The study collected data regarding current treatment and absolute PASI and their relationship to HRQoL using the Dermatology Life Quality Index (DLQI), to activity impairment using the Work Productivity and Activity Impairment (WPAI) questionnaire, and to treatment satisfaction. RESULTS: The mean (SD) age was 50.5 (12.5) years, with a duration of disease of 14 (14.1) years. The mean (SD) absolute PASI reported was 2.3 (3.5), with 28.7% of patients presenting with PASI from >1 to ≤3 and 22.6% with PASI>3. Higher PASI scores were associated with higher DLQI (p<0.001) and WPAI scores and lower levels of treatment satisfaction (p<0.001). CONCLUSIONS: These data indicate that achieving lower absolute PASI values may correlate not only with better HRQoL but also with better work productivity and treatment satisfaction.
Subject(s)
Psoriasis , Quality of Life , Humans , Adolescent , Young Adult , Adult , Middle Aged , Aged , Spain/epidemiology , Cross-Sectional Studies , Psoriasis/complications , Psoriasis/drug therapy , Skin , Severity of Illness Index , Treatment OutcomeABSTRACT
BACKGROUND AND OBJECTIVE: The treatment of psoriasis should not only focus on skin affectations but also weigh the parameters for health-related quality of life (HRQoL), thereby tackling the concept of cumulative life course impairment (CLCI) and treating the patient from a holistic perspective. The CRYSTAL study aimed to characterize psoriasis with real-word data from Spanish clinical practice in patients with moderate to severe disease who received continuous systemic treatment for at least 24 weeks by using the absolute Psoriasis Area and Severity Index (PASI) score and its correlation to HRQoL. MATERIAL AND METHODS: This was a non-interventional, cross-sectional study conducted in 30 centers in Spain, with 301 patients between the ages of 18 and 75 years. The study collected data regarding current treatment and absolute PASI and their relationship to HRQoL using the Dermatology Life Quality Index (DLQI), to activity impairment using the Work Productivity and Activity Impairment (WPAI) questionnaire, and to treatment satisfaction. RESULTS: The mean (SD) age was 50.5 (12.5) years, with a duration of disease of 14 (14.1) years. The mean (SD) absolute PASI reported was 2.3 (3.5), with 28.7% of patients presenting with PASI from >1 to ≤3 and 22.6% with PASI>3. Higher PASI scores were associated with higher DLQI (p<0.001) and WPAI scores and lower levels of treatment satisfaction (p<0.001). CONCLUSIONS: These data indicate that achieving lower absolute PASI values may correlate not only with better HRQoL but also with better work productivity and treatment satisfaction.
Subject(s)
Psoriasis , Quality of Life , Humans , Adolescent , Young Adult , Adult , Middle Aged , Aged , Spain/epidemiology , Cross-Sectional Studies , Psoriasis/complications , Psoriasis/drug therapy , Skin , Severity of Illness Index , Treatment OutcomeABSTRACT
El carcinoma adenoide quístico cutáneo primario es un raro tumor de baja malignidad, que se manifiesta clínicamente como un nódulo duro y mal (..) (AU)
Primary cutaneous adenoid cystic carcinoma is a rare tumor with (..) (AU)
